Bone Status on Patients With Genetic Hemochromatosis: a 3 Years Descriptive and Evolutionary Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to describe bone status on patients with genetic hemochromatosis, at diagnostic time and his evolution under treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transferrin Saturation and Asthenia in Hemochromatosis

NCT03356548

Hemochromatoses, Genetic

COMPLETED

Cohort of Patients With Rare Iron Overloads Excluding C282Y Homozygosity

NCT02619955

Rare Iron Overlaods

COMPLETED

Impact of Bloodletting on Iron Metabolism in Type 1 Hemochromatosis

NCT01810965

Hemochromatosis Type 1

COMPLETED NA

Hemochromatosis--Genetic Prevalence and Penetrance

NCT00006312

Blood Disease Hemochromatosis

COMPLETED

Rare Iron Overloads Except C282Y Homozygosity : Description and Characterization.

NCT01541813

Rare Iron Overloads Except C282Y Homozygosity

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Bone diseases have been recognized recently as complications of genetic hemochromatosis. Further studies are needed to describe the role of iron in bone injuries. The purpose of this study is to describe bone status on patients with genetical hemochromatosis, at diagnostic time and his evolution under treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Genetic Hemochromatosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients between 18 and 80 years
* C282 homozygosity

Exclusion Criteria

* corticosteroids during the last 3 months
* following treatments during the last 6 months : anabolic steroids, growth hormone, hormone therapy for menopause, tibolone, raloxifene.
* following treatments during inclusion or in the last 6 month : teriparatide, parathormone, fluor, strontium ranelate, biphosphonate.
* cancer or evolutionary hemopathy (including monoclonal gammopathy)
* pregnancy at inclusion time
* treated osteoporosis
* patient in wich follow up seems hard
* inclusion in another study incompatible with this one

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No